Insiders Advisor
  • Stocks
  • World News
  • Business
  • Politics
  • Stocks
  • World News
  • Business
  • Politics

Insiders Advisor

Stocks

DexCom Stock Rises From the Ashes: A Breakout You Can’t Ignore

by January 17, 2025
January 17, 2025
DexCom Stock Rises From the Ashes: A Breakout You Can’t Ignore

As advancements in medical technology continue to shape the healthcare landscape, DexCom, Inc. (DXCM) stands out with its innovative continuous glucose monitoring solutions. Recent price action suggests that DXCM’s stock price has triggered a potentially new bullish run. In this article, I will examine the technical and fundamental factors behind this positive outlook and outline a risk-defined options strategy — all identified via the OptionsPlay Strategy Center within StockCharts.com.

After consolidating between $75 and $80 over the past two months, DXCM’s stock price recently broke out of this trading range with impressive relative strength.

  • Range Breakout. The stock’s breakout above $80 marks a decisive breakout from its consolidation zone.
  • Outperformance. The breakout has been coupled with outperformance to the S&P 500.
  • Upside Target. Given the breakout, there is potential for DXCM’s stock price to fill the gap up to the $107.50 level.

FIGURE 1. DAILY CHART OF DXCM STOCK. The stock price traded between $75 and $80 since the end of November. DXCM recently broke out of its consolidation zone and traded above $80.Chart source: StockCharts.com. For educational purposes.

Beyond the charts, DXCM’s fundamentals support its premium valuation:

  • Premium but justified. While trading at 39x forward earnings, DXCM’s superior growth expectations and higher net margins than peers suggest that this valuation is justified.
  • Potential for substantial upside. Robust demand in the continuous glucose monitoring market and DexCom’s leadership position the company to capitalize on ongoing trends. The combination of strong growth prospects and healthy margins provides the potential for further appreciation.

Options Strategy

Based on this bullish thesis, the OptionsPlay Strategy Center highlights a bull put spread.

  • Sell: February 28, 2025, $84 Put at $5.40
  • Buy: February 28, 2025, $77 Put at $2.42
  • Net Credit: $2.98 per share (or $298 total per contract, since each contract represents 100 shares)

FIGURE 2. DXCM BULL PUT SPREAD RISK CURVE.

Trade Details

  • Maximum Potential Reward: $298
  • Maximum Potential Risk: $402
  • Breakeven Point: $81.02
  • Probability of Profit: 58.58%

This strategy benefits from time decay and a bullish outlook, providing limited risk and a defined reward. At expiration, profits are earned if DXCM’s stock price remains above the breakeven level.

Unlock Real-Time Trade Ideas

This bullish trade in DXCM was identified using the OptionsPlay Strategy Center within StockCharts.com. The platform’s Bullish Outperform scan (see below) automatically flagged DXCM as the best candidate for selling a Bull Put Spread out of the many stocks currently outperforming the market, then structured the optimal options trade — helping you save hours of research.

FIGURE 3. BULLISH OUTPERFORMANCE SCAN. DXCM was identified as a candidate for a bull put spread.


By subscribing to the OptionsPlay Strategy Center, you gain access to:

  •  Automated Market Scans. Quickly discover high-probability trading opportunities based on technical and fundamental signals.
  • Optimal Trade Structuring. Receive tailored, real-time options strategies for your market outlook and risk tolerance.
  • Time-Saving Insights. Make informed decisions faster, avoiding the time-consuming process of manual analysis.

Don’t miss out on your next high-conviction idea. Subscribe to the OptionsPlay Strategy Center today and unlock a streamlined approach to uncovering the best options trades—all within seconds, every single day. Let OptionsPlay be your strategic ally in navigating the markets efficiently and effectively.

previous post
RNC chair Whatley vows to be ‘tip of the spear’ to protect Trump after coasting to reelection victory
next post
FDA officially authorizes Zyn nicotine pouches for sale following health review

Related Posts

Fintech is Leading and Providing a Good Hunting...

December 7, 2024

How to Chart In Multiple Timeframes Like A...

April 20, 2024

Rules-Based Money Management – Part 5: Security Selection,...

May 16, 2024

DP Trading Room: A Case for a Market...

October 7, 2024

Nvidia Plunges Over 6% to Mark the End...

June 25, 2024

Using Outsized Moves to Identify Trend Reversals –...

April 12, 2024

Sector Spotlight: Dominant Trend for Stocks Still UP

February 20, 2024

Week Ahead: NIFTY Stays Tentative As Defensive Setup...

August 10, 2024

Stock Market Today: Two Sectors That Can Make...

August 27, 2024

Bitcoin Blasts ABOVE 70K!

May 21, 2024

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Latest News

    • ‘Get a job’: Medicaid work requirements included in Trump’s megabill sparks partisan debate on Capitol Hill

      July 19, 2025
    • Musk’s brain implant company filed as a ‘disadvantaged business’

      July 19, 2025
    • Trump has now been in office for six months, for the second time. Here are the highlights

      July 19, 2025
    • Slovenia approves law to legalize assisted dying for terminally-ill adults

      July 19, 2025
    • Heritage Foundation founder Edwin J. Feulner dies at 83

      July 19, 2025
    • Rubio announces visa revocations on Brazilian judge for ‘political witch hunt’ against ex-president Bolsonaro

      July 19, 2025

    Categories

    • Business (1,311)
    • Politics (6,469)
    • Stocks (904)
    • World News (460)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: insidersadvisor.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 insidersadvisor.com | All Rights Reserved